Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis

104-Week results of the GO-RAISE study

Jürgen Braun, Atulya (Atul) Deodhar, Robert D. Inman, Désirée Van Der Heijde, Michael Mack, Stephen Xu, Benjamin Hsu

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Objective: To assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis. Methods: At baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcutaneous injections of placebo (group 1), golimumab 50 mg (group 2) or golimumab 100 mg (group 3) every 4 weeks. At week 16, patients in groups 1 and 2 with

Original languageEnglish (US)
Pages (from-to)661-667
Number of pages7
JournalAnnals of the Rheumatic Diseases
Volume71
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Ankylosing Spondylitis
Subcutaneous Injections
Placebos
Safety
golimumab

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis : 104-Week results of the GO-RAISE study. / Braun, Jürgen; Deodhar, Atulya (Atul); Inman, Robert D.; Van Der Heijde, Désirée; Mack, Michael; Xu, Stephen; Hsu, Benjamin.

In: Annals of the Rheumatic Diseases, Vol. 71, No. 5, 05.2012, p. 661-667.

Research output: Contribution to journalArticle

Braun, Jürgen ; Deodhar, Atulya (Atul) ; Inman, Robert D. ; Van Der Heijde, Désirée ; Mack, Michael ; Xu, Stephen ; Hsu, Benjamin. / Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis : 104-Week results of the GO-RAISE study. In: Annals of the Rheumatic Diseases. 2012 ; Vol. 71, No. 5. pp. 661-667.
@article{b23b267afbf54e4b86947fde5686096c,
title = "Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-Week results of the GO-RAISE study",
abstract = "Objective: To assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis. Methods: At baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcutaneous injections of placebo (group 1), golimumab 50 mg (group 2) or golimumab 100 mg (group 3) every 4 weeks. At week 16, patients in groups 1 and 2 with",
author = "J{\"u}rgen Braun and Deodhar, {Atulya (Atul)} and Inman, {Robert D.} and {Van Der Heijde}, D{\'e}sir{\'e}e and Michael Mack and Stephen Xu and Benjamin Hsu",
year = "2012",
month = "5",
doi = "10.1136/ard.2011.154799",
language = "English (US)",
volume = "71",
pages = "661--667",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis

T2 - 104-Week results of the GO-RAISE study

AU - Braun, Jürgen

AU - Deodhar, Atulya (Atul)

AU - Inman, Robert D.

AU - Van Der Heijde, Désirée

AU - Mack, Michael

AU - Xu, Stephen

AU - Hsu, Benjamin

PY - 2012/5

Y1 - 2012/5

N2 - Objective: To assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis. Methods: At baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcutaneous injections of placebo (group 1), golimumab 50 mg (group 2) or golimumab 100 mg (group 3) every 4 weeks. At week 16, patients in groups 1 and 2 with

AB - Objective: To assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis. Methods: At baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcutaneous injections of placebo (group 1), golimumab 50 mg (group 2) or golimumab 100 mg (group 3) every 4 weeks. At week 16, patients in groups 1 and 2 with

UR - http://www.scopus.com/inward/record.url?scp=84859509505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859509505&partnerID=8YFLogxK

U2 - 10.1136/ard.2011.154799

DO - 10.1136/ard.2011.154799

M3 - Article

VL - 71

SP - 661

EP - 667

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 5

ER -